| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2849223 | American Heart Journal | 2007 | 6 Pages |
Abstract
This article is going to be somewhat different than the typical article you might read on the treatment of heart failure. My goal is to get you to think in a different way about the use of primary prevention implantable cardioverter defibrillators and β-blockers in patients with left ventricular dysfunction. Specifically, using the results from 3 landmark clinical trials—MADIT II, SCD-HeFT, and COMET—I am going to discuss the economic, ethical, and legal principles that underpin the use of these 2 therapies in patients with heart failure.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marc T. Silver,